Measuring costs

administrative claims data, clinical trials, and beyond.

Ruth Etzioni, Gerald F. Riley, Scott D. Ramsey, Martin Brown

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

BACKGROUND: Accurate estimation of medical care costs raises a host of issues, both practical and methodological. OBJECTIVES: This article reviews methods for estimating the long-term medical care costs associated with a cancer diagnosis. METHODS: The authors consider data from administrative claims databases and describe the analytic challenges posed by these increasingly common resources. They present a number of statistical methods that are valid under censoring and describe methods for estimating mean costs and controlling for covariates. In addition, the authors compare two different approaches for estimating the cancer-related costs; namely, the portion of the long-term costs that may be attributed to the disease. Examples from economic studies of breast and colorectal cancer are presented. RESULTS: In an analysis of data on colorectal cancer costs from the SEER-Medicare database, the two methods used to estimate expected long-term costs (one model based, one not model-based) yielded similar results. However, in calculating expected cancer-related costs, a method that included future medical costs among controls yielded quite different results from the method that did not include these future costs. CONCLUSIONS: Statistical methods for analyzing long-term medical costs under censoring are available and appropriate in many applications where total or disease-related costs are of interest. Several of these approaches are nonparametric and therefore may be expected to be robust against the non-standard features that are often encountered when analyzing medical cost data.

Original languageEnglish (US)
JournalMedical care
Volume40
Issue number6 Suppl
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Clinical Trials
Costs and Cost Analysis
Health Care Costs
Colorectal Neoplasms
Databases
Neoplasms
Cost of Illness
Cost Control
Long-Term Care
Medicare
Economics
Breast Neoplasms

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Etzioni, R., Riley, G. F., Ramsey, S. D., & Brown, M. (2002). Measuring costs: administrative claims data, clinical trials, and beyond. Medical care, 40(6 Suppl).

Measuring costs : administrative claims data, clinical trials, and beyond. / Etzioni, Ruth; Riley, Gerald F.; Ramsey, Scott D.; Brown, Martin.

In: Medical care, Vol. 40, No. 6 Suppl, 01.01.2002.

Research output: Contribution to journalReview article

Etzioni, R, Riley, GF, Ramsey, SD & Brown, M 2002, 'Measuring costs: administrative claims data, clinical trials, and beyond.', Medical care, vol. 40, no. 6 Suppl.
Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: administrative claims data, clinical trials, and beyond. Medical care. 2002 Jan 1;40(6 Suppl).
Etzioni, Ruth ; Riley, Gerald F. ; Ramsey, Scott D. ; Brown, Martin. / Measuring costs : administrative claims data, clinical trials, and beyond. In: Medical care. 2002 ; Vol. 40, No. 6 Suppl.
@article{66194f8749c84d758c9dea06f46629ed,
title = "Measuring costs: administrative claims data, clinical trials, and beyond.",
abstract = "BACKGROUND: Accurate estimation of medical care costs raises a host of issues, both practical and methodological. OBJECTIVES: This article reviews methods for estimating the long-term medical care costs associated with a cancer diagnosis. METHODS: The authors consider data from administrative claims databases and describe the analytic challenges posed by these increasingly common resources. They present a number of statistical methods that are valid under censoring and describe methods for estimating mean costs and controlling for covariates. In addition, the authors compare two different approaches for estimating the cancer-related costs; namely, the portion of the long-term costs that may be attributed to the disease. Examples from economic studies of breast and colorectal cancer are presented. RESULTS: In an analysis of data on colorectal cancer costs from the SEER-Medicare database, the two methods used to estimate expected long-term costs (one model based, one not model-based) yielded similar results. However, in calculating expected cancer-related costs, a method that included future medical costs among controls yielded quite different results from the method that did not include these future costs. CONCLUSIONS: Statistical methods for analyzing long-term medical costs under censoring are available and appropriate in many applications where total or disease-related costs are of interest. Several of these approaches are nonparametric and therefore may be expected to be robust against the non-standard features that are often encountered when analyzing medical cost data.",
author = "Ruth Etzioni and Riley, {Gerald F.} and Ramsey, {Scott D.} and Martin Brown",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "40",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "6 Suppl",

}

TY - JOUR

T1 - Measuring costs

T2 - administrative claims data, clinical trials, and beyond.

AU - Etzioni, Ruth

AU - Riley, Gerald F.

AU - Ramsey, Scott D.

AU - Brown, Martin

PY - 2002/1/1

Y1 - 2002/1/1

N2 - BACKGROUND: Accurate estimation of medical care costs raises a host of issues, both practical and methodological. OBJECTIVES: This article reviews methods for estimating the long-term medical care costs associated with a cancer diagnosis. METHODS: The authors consider data from administrative claims databases and describe the analytic challenges posed by these increasingly common resources. They present a number of statistical methods that are valid under censoring and describe methods for estimating mean costs and controlling for covariates. In addition, the authors compare two different approaches for estimating the cancer-related costs; namely, the portion of the long-term costs that may be attributed to the disease. Examples from economic studies of breast and colorectal cancer are presented. RESULTS: In an analysis of data on colorectal cancer costs from the SEER-Medicare database, the two methods used to estimate expected long-term costs (one model based, one not model-based) yielded similar results. However, in calculating expected cancer-related costs, a method that included future medical costs among controls yielded quite different results from the method that did not include these future costs. CONCLUSIONS: Statistical methods for analyzing long-term medical costs under censoring are available and appropriate in many applications where total or disease-related costs are of interest. Several of these approaches are nonparametric and therefore may be expected to be robust against the non-standard features that are often encountered when analyzing medical cost data.

AB - BACKGROUND: Accurate estimation of medical care costs raises a host of issues, both practical and methodological. OBJECTIVES: This article reviews methods for estimating the long-term medical care costs associated with a cancer diagnosis. METHODS: The authors consider data from administrative claims databases and describe the analytic challenges posed by these increasingly common resources. They present a number of statistical methods that are valid under censoring and describe methods for estimating mean costs and controlling for covariates. In addition, the authors compare two different approaches for estimating the cancer-related costs; namely, the portion of the long-term costs that may be attributed to the disease. Examples from economic studies of breast and colorectal cancer are presented. RESULTS: In an analysis of data on colorectal cancer costs from the SEER-Medicare database, the two methods used to estimate expected long-term costs (one model based, one not model-based) yielded similar results. However, in calculating expected cancer-related costs, a method that included future medical costs among controls yielded quite different results from the method that did not include these future costs. CONCLUSIONS: Statistical methods for analyzing long-term medical costs under censoring are available and appropriate in many applications where total or disease-related costs are of interest. Several of these approaches are nonparametric and therefore may be expected to be robust against the non-standard features that are often encountered when analyzing medical cost data.

UR - http://www.scopus.com/inward/record.url?scp=0036618026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036618026&partnerID=8YFLogxK

M3 - Review article

VL - 40

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 6 Suppl

ER -